Renewed Interest in Psychedelic Treatment for Behavioral Health Conditions (Podcast)

Research shows promise for use in therapeutic settings to manage depression, PTSD, anxiety and more

Advertising Policy

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy

Psychedelic drugs have reemerged in recent years as a promising treatment for a variety of behavioral health diagnoses, such as depression, post-traumatic stress disorder and generalized anxiety disorder.

“If patients go into the psychedelic experience with therapeutic intent and in a therapeutic setting, they can get benefits that may last for a year or even longer in some cases,” says Brian Barnett, MD, a psychiatrist in Cleveland Clinic’s Center for Behavioral Health.

Dr. Barnett discusses the current state of psychedelics research and what’s next for the field in the latest episode of Cleveland Clinic’s Neuro Pathways podcast. He covers:

Advertising Policy
  • Drugs at the forefront of psychedelic research, including psilocybin and MDMA
  • Potential applications for psychedelics in therapy
  • Safety concerns and abuse risk with these medications
  • Major challenges facing researchers in the field
  • Budding interest in psychedelics to treat dementia and chronic pain

Click the podcast player above to listen to the 28-minute episode now, or read on for a short edited excerpt. Check out more Neuro Pathways episodes at or wherever you get your podcasts. This activity has been approved for AMA PRA Category 1 Credit™. After listening to the podcast, you can claim your credit here.

Excerpt from the podcast

Podcast host Glen Stevens, DO, PhD: How well do we understand the mechanism of action of these drugs?

Dr. Barnett: In psychiatry in general, we don’t know a lot about how many of our treatments work. We have inklings here and there from different types of studies, but it looks like the primary mechanism at the neuronal level is that psychedelics activate the serotonin 2A pathway, so 5-HT2A. That pathway is involved in a number of areas — including learning, memory, pain perception and the sleep-wake cycle — but those receptors are most concentrated in what are called the higher-order association areas of the brain.

Advertising Policy

Those are the parts of the brain that integrate incoming sensory information, and it looks like psychedelics really allow more sensory input to enter the brain. They peel back the thalamus’s control over sensory input data, allowing more sensory data to come in, which overloads the brain and causes different areas that normally don’t talk to each other to communicate and connect. That is why people sometimes can get what’s called synesthesia when they take a psychedelic — experiencing sound as colors and things like that.

And from a different perspective, it appears that taking a psychedelic induces pretty long-lasting periods of neuroplasticity, where the brain is more flexible. During these periods, the brain is better able to reorganize synaptic connections, allowing a person to really adjust their perspective on things, see life from a different point of view, learn new ways of coping with stress. This is why we think that the period of several weeks afterward — maybe even several months — is when a lot of the therapeutic benefit comes, because patients can really engage in therapy at that point, and therapy can be catalyzed.